2015;55(2):1-10. Surveys performed in 2009 indicated that >80% of retina specialists used topical antibiotics either before and/or after IVT injections. More recent surveys, however, have ...

The rapid growth in IVT injections has resulted from the introduction of novel drug therapies. In 2004, only 2 agents were specifically approved by the United States Food and Drug Administration ...

Adverum Biotechnologies advances wet AMD treatment with promising trial results. See why ADVM stock has potential as it ...

Both LUNA and OPTIC were designed to assess a broad wet AMD population, including hard-to-treat patients with severe disease ...

Outlook Therapeutics OTLK reported preliminary top-line results from the 90-day non-inferiority NORSE EIGHT clinical study ...

Swiss generic and biosimilar medicines major Sandoz today announced that the European Commission (EC) has granted marketing ...

The study confirmed that Afqlir has equivalent efficacy and comparable safety to its reference medicine, Eylea.

Detailed price information for Adverum Biotechnologies Inc (ADVM-Q) from The Globe and Mail including charting and trades.

Designed as a single, one-time intravitreal injection, Ixo-vec has the potential to extend therapeutic benefit from weeks to years. Today’s 4-year OPTIC data suggest that Ixo-vec may preserve vision ...